Arkolith/Insider Trading/URGN/Form 4

Schoenberg Mark

Chief Medical OfficerUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Sep 12, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$11K
Net Open-Market Flow
-$11K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 9, 2024Option exercise(M)2K——146K
Sep 9, 2024Sell(S)859$13.08$11K145K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 9, 2024Option exercise(M)2K—$03K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-24-029040) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML